source
- FDA approves Revolution Medicines' Rasonque for metastatic pancreatic cancerRevolution Medicines received FDA approval for its oral RAS inhibitor daraxonrasib, branded as Rasonque, to treat patients with metastatic pancreatic adenocarcinoma who have already received prior…
- FDA grants rapid approval to Revolution Medicines' pancreatic cancer drug RasonqueFDA approved Revolution Medicines' pancreatic cancer therapy Rasonque, just over a month after submission using a priority review voucher. The drug, formerly known as daraxonrasib, is for patients…